Naltrexone 4.5mg Capsules are a low-dose naltrexone (LDN) formulation containing 4.5mg of naltrexone hydrochloride per capsule. LDN refers to doses substantially lower than the standard 50mg oral naltrexone regimen used for approved indications. Low-dose naltrexone is used by some healthcare professionals for selected off-label conditions, but 4.5mg LDN is not an FDA-approved indication or standardized FDA-approved dosage form.
Naltrexone is an opioid receptor antagonist. At conventional doses, oral naltrexone is FDA-approved for alcohol dependence and for blocking the effects of externally administered opioids. The use of lower doses such as 4.5mg for other conditions is considered off-label and should be determined by a qualified healthcare professional.
Low-Dose Naltrexone (LDN) describes the use of naltrexone at doses considerably below the standard 50mg oral dose.
A 4.5mg capsule is therefore commonly marketed and searched for as LDN 4.5mg, Low Dose Naltrexone 4.5mg, or Naltrexone 4.5mg Capsules.
The FDA-approved oral naltrexone labeling concerns 50mg tablets for alcohol dependence and blockade of the effects of externally administered opioids. The FDA explains that prescribing an approved drug for a different condition or at a different dose is considered off-label use.
LDN is commonly discussed in clinical and patient communities in connection with a variety of chronic conditions. However, the evidence base differs substantially by condition, and many proposed LDN applications remain investigational or off-label.
A healthcare professional may consider LDN in an individualized treatment plan when appropriate.
Do not represent LDN 4.5mg as FDA-approved treatment for a specific off-label condition.
Both products contain naltrexone hydrochloride, but the dose is substantially different.
| Product | Strength | Common regulatory use |
|---|---|---|
| Naltrexone Tablet | 50mg | Alcohol dependence and opioid blockade |
| Naltrexone 4.5mg Capsule | 4.5mg | Low-dose/off-label use under medical supervision |
The FDA-approved labeling for oral naltrexone specifies 50mg tablets for alcohol dependence and blockade of externally administered opioids.
Naltrexone is a pure opioid antagonist. It binds to opioid receptors and blocks or substantially reduces the effects of opioid agonists. It does not produce the opioid agonist effects associated with medicines such as morphine.
The biological effects of lower-dose naltrexone are an area of ongoing research. Proposed mechanisms for LDN in different conditions should not be presented as established therapeutic mechanisms.
LDN 4.5mg is commercially searched in connection with several chronic conditions, including:
These applications are generally off-label, and the level of clinical evidence varies considerably between conditions.
The product should therefore be positioned as Low-Dose Naltrexone (LDN) rather than claiming that 4.5mg is an approved treatment for these diseases.
Low-dose naltrexone is being studied and used by some clinicians for selected chronic pain conditions.
Research interest includes conditions involving chronic or neuropathic pain, but evidence is not equivalent to the established evidence supporting conventional naltrexone’s FDA-approved indications.
Patients should receive an appropriate diagnosis before LDN is considered.
Low-Dose Naltrexone for fibromyalgia is a commonly searched application.
Some clinical studies have investigated low-dose naltrexone in fibromyalgia, but this remains an off-label use rather than an FDA-approved indication.
Treatment decisions should consider the available evidence, alternative treatments and the patient’s individual circumstances.
LDN has also been investigated in relation to multiple sclerosis (MS), including symptom-related outcomes.
It is not an FDA-approved disease-modifying treatment for multiple sclerosis. It should not be presented as a replacement for established MS disease-modifying therapies.
Low-dose naltrexone is sometimes discussed in relation to inflammatory and immune-mediated conditions.
However, claims that LDN is a proven general-purpose anti-inflammatory treatment should be avoided. Evidence and clinical recommendations vary substantially by condition.
A 4.5mg capsule is a specific low-dose formulation. The appropriate LDN regimen depends on the patient’s condition, treatment history, concurrent medicines and prescriber’s clinical judgment.
Do not automatically assume that 4.5mg is appropriate for every patient using LDN.
Naltrexone dose changes should be made only under the direction of the prescribing healthcare professional.
Possible adverse effects of naltrexone can include:
Individual tolerability can vary.
Naltrexone can also cause clinically significant liver-related adverse effects, particularly at higher exposures, so patients with liver disease require appropriate medical evaluation.
This is one of the most important safety considerations.
Naltrexone blocks opioid receptors. Patients receiving opioid analgesics or who are currently opioid-dependent should not start naltrexone without appropriate medical assessment. Naltrexone can precipitate severe opioid withdrawal in opioid-dependent individuals.
This applies even though the LDN dose is lower than the conventional 50mg dose.
Patients taking opioid-containing medicines should tell their healthcare professional before using LDN.
Naltrexone may interfere with opioid analgesia.
Patients using LDN should inform their doctor, dentist, surgeon or emergency-care provider that they are taking naltrexone before procedures where opioid pain medication may be considered.
Do not attempt to overcome opioid receptor blockade by taking larger opioid doses, as this can create serious overdose risk.
Naltrexone is metabolized by the liver, and caution is required in patients with liver disease.
A healthcare professional may assess liver function according to the patient’s clinical history and treatment circumstances.
Seek medical attention for symptoms such as:
Potentially important interactions include:
Provide your healthcare professional with a complete list of medicines and supplements before starting LDN.
The standard FDA-approved oral naltrexone indication includes treatment of alcohol dependence. However, LDN 4.5mg should not automatically be represented as equivalent to the approved 50mg alcohol-dependence regimen.
The FDA-approved labeling specifies 50mg once daily for most patients being treated for alcohol dependence.
Naltrexone is sometimes discussed online in connection with weight management.
However, naltrexone 4.5mg alone should not be marketed as an FDA-approved weight-loss medicine. The use of LDN for weight management is not the same as an approved weight-loss indication.
Naltrexone 4.5mg capsules contain naltrexone alone.
Naltrexone/bupropion combination products contain two active ingredients and are a different prescription medicine with different indications, dosing and safety considerations.
They should not be treated as interchangeable products.
Naltrexone 4.5mg Capsules are commonly searched commercially as Low-Dose Naltrexone (LDN) and may be supplied as a prescription or compounded formulation depending on the country and pharmacy.
High-intent searches include Naltrexone 4.5mg Capsules, Low Dose Naltrexone 4.5mg, LDN 4.5mg Capsules, LDN Capsules, Low Dose Naltrexone Capsules, Naltrexone 4.5mg Online, Buy LDN 4.5mg, Buy Low Dose Naltrexone, Naltrexone 4.5mg Price and Low Dose Naltrexone Pharmacy.
Availability, compounding requirements, prescription status and import rules vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.
Naltrexone 4.5mg is a low-dose oral formulation of naltrexone hydrochloride, commonly referred to as Low-Dose Naltrexone or LDN.
LDN stands for Low-Dose Naltrexone.
Yes. A 4.5mg naltrexone formulation falls within the low-dose range commonly referred to as LDN.
LDN 4.5mg is prescribed by some healthcare professionals for selected off-label conditions. Uses vary, and 4.5mg LDN does not have an FDA-approved indication for these off-label applications.
The FDA has approved naltrexone for specific uses at conventional doses, including alcohol dependence and blockade of externally administered opioids. LDN 4.5mg for other conditions is not an FDA-approved indication.
Some healthcare professionals prescribe LDN off-label for fibromyalgia, and it has been studied for this condition. It is not an FDA-approved fibromyalgia treatment.
LDN has been studied and prescribed off-label for selected chronic pain conditions. Evidence varies according to the specific diagnosis.
LDN has been investigated for MS-related symptoms, but it is not an FDA-approved disease-modifying treatment for multiple sclerosis.
Naltrexone can block opioid medicines and can precipitate withdrawal in opioid-dependent patients. Anyone using opioid medication should discuss LDN with their healthcare professional before starting treatment.
No. They contain the same active ingredient, but 4.5mg is substantially lower than the conventional 50mg oral naltrexone dose.
Naltrexone is a prescription medicine. LDN formulations may also involve pharmacy compounding depending on the market. Purchase should be through an appropriately licensed pharmacy or authorized supplier and used under professional supervision.
LDN availability varies considerably because 4.5mg formulations may be compounded and regulatory requirements differ between countries.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Naltrexone 4.5mg/LDN is commonly used for off-label purposes, and the FDA has not established safety and effectiveness for those uses. Naltrexone can precipitate severe opioid withdrawal and interfere with opioid analgesics. Patients should disclose all opioid use and relevant medical conditions to their healthcare professional before treatment. Always consult a qualified healthcare professional before starting, stopping or changing LDN therapy.
Last Updated: August 24, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Naltrexone 4.5mg Capsules
Reviews
There are no reviews yet